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Abstract
: The Antifibrinolytic Trialists Collaboration aims to increaseIntroduction
knowledge about the effectiveness and safety of antifibrinolytic treatment by
conducting individual patient data (IPD) meta-analyses of randomised trials.
This article presents the statistical analysis plan for an IPD meta-analysis of the
effects of antifibrinolytics for acute intracranial haemorrhage.
: The protocol for the IPD meta-analysis has been registered withMethods
PROSPERO (CRD42016052155). We will conduct an individual patient data
meta-analysis of randomised controlled trials with 1000 patients or more
assessing the effects of antifibrinolytics in acute intracranial haemorrhage. We
will assess the effect on two co-primary outcomes: 1) death in hospital at end of
trial follow-up, and 2) death in hospital or dependency at end of trial follow-up.
The co-primary outcomes will be limited to patients treated within three hours of
injury or stroke onset. We will report treatment effects using odds ratios and
95% confidence intervals. We use logistic regression models to examine how
the effect of antifibrinolytics vary by time to treatment, severity of intracranial
bleeding, and age. We will also examine the effect of antifibrinolytics on
secondary outcomes including death, dependency, vascular occlusive events,
seizures, and neurological outcomes. Secondary outcomes will be assessed in
all patients irrespective of time of treatment. All analyses will be conducted on
an intention-to-treat basis.
: This IPD meta-analysis will examine important clinical questionsConclusions
about the effects of antifibrinolytic treatment in patients with intracranial
haemorrhage that cannot be answered using aggregate data. With IPD we can
examine how effects vary by time to treatment, bleeding severity, and age, to
gain better understanding of the balance of benefit and harms on which to base
recommendations for practice.
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Introduction
Traumatic and spontaneous intracranial bleeding are leading 
causes of death and disability worldwide. Traumatic brain injury, 
responsible for over 10 million deaths or hospitalisations each 
year1, is often accompanied by intracranial bleeding and the 
larger the bleed the worse the outcome2. Bleeding continues after 
hospital admission in most patients with moderate or severe 
traumatic brain injuries3. Haemorrhagic stroke affects about six 
million people every year worldwide4. About three million die and 
many survivors are permanently disabled4. Once again, bleeding 
can continue for up to 24 hours after stroke onset, although 
is most common in the first few hours5. The continuation of 
bleeding in the hours after onset in both traumatic and spontane-
ous intracranial bleeding, offers a therapeutic window to reduce 
the extent of the bleeding and improve patient outcomes.
Antifibrinolytics reduce bleeding by inhibiting the enzymatic 
breakdown of fibrin blood clots. They reduce surgical bleeding 
by about one third, irrespective of the site of surgery6,7. When 
given within three hours of onset, the antifibrinolytic tranexamic 
acid (TXA) reduces death due to bleeding in trauma and postpar-
tum haemorrhage, with no evidence of heterogeneity by type of 
bleeding8. However, in both trauma and postpartum haemor-
rhage there is no apparent benefit when treatment starts more than 
three hours after bleeding onset. TXA does not appear to increase 
the risk of thromboembolic events in extracranial bleeding7–9.
The improved outcomes with antifibrinolytics treatment in 
extracranial bleeding raises the possibility that they might improve 
outcomes after intracranial bleeding. There have been two 
small trials of TXA in traumatic brain injury10,11; both recruited 
patients within eight hours of injury. A meta-analysis showed 
a significant reduction in haemorrhage expansion with TXA12. 
However, even when combined the trials are too small to deter-
mine the overall risks and benefits, and whether these vary with 
treatment delay. Larger trials are ongoing. Trials of TXA in 
aneurysmal subarachnoid haemorrhage show less re-bleeding 
but more ischemia13. However, the long courses of treatment 
in these trials, unlike the eight-hour courses used in extracranial 
bleeding, may account for the increase in ischaemia. Larger trials 
of shorter regimens are underway14,15.
The Antifibrinolytic Trialists Collaboration (ATC) aims to 
increase knowledge about the effectiveness and safety of antifi-
brinolytic treatment by conducting individual patient data (IPD) 
meta-analyses of randomised trials of antifibrinolytics in acute 
severe bleeding involving 1000 patients or more. This article 
presents the statistical analysis plan for an IPD meta-analysis of 
the effects of antifibrinolytics in acute intracranial haemorrhage. 
There are two ongoing trials of TXA in patients with intracra-
nial haemorrhage that meet the inclusion criteria for the IPD, the 
CRASH-3 and TICH-2 clinical trials14,16. This plan was prepared 
prior to any knowledge of the results of either the CRASH-3 or 
TICH-2 trials.
Methods
Identification of eligible trials
We will conduct an individual patient data meta-analysis of 
randomised placebo-controlled trials with 1000 patients or more 
that assessed the effects of antifibrinolytics (aprotinin, tranexamic 
acid, epsilon-aminocaproic acid and p-aminomethylbenzoic 
acid) in acute intracranial haemorrhage. We will identify trials 
from a register of antifibrinolytic trials maintained by the LSHTM 
Clinical Trials Unit. We identify trials by running searches of 
the following databases: MEDLINE, EMBASE, the Cochrane 
Central Register of Controlled Trials (CENTRAL), Web of 
Science, PubMed, Popline and the WHO International Clinical 
Trials Registry Platform. We will screen abstracts for relevant 
trials and apply the relevant selection criteria. We discuss rea-
sons for exclusion and resolve discrepancies by consensus. Two 
reviewers will extract data to minimise bias. We will analyse 
individual patient data for baseline, outcome, and predictor 
variables; dates and times of randomisation and death. We regis-
tered the protocol in November 2016 (PROSPERO 42016052155) 
without any knowledge of the results of the large ongoing trials. 
We judge that separate institutional review board (IRB) approval 
for this study is not required. This project involves the analysis of 
existing trial data. Each trial providing individual patient data will 
have received local ethical approval. The planned study will not 
require further recruitment or data collection from patients and 
the analysis will not include identifiable data. The lead investiga-
tors of the CRASH-3 and TICH-2 trials agree that use of the IPD 
data from their trials does not require separate ethics commit-
tee approval. If, however, there is uncertainty about the use of 
data from any other trial that we subsequently identify, we will 
seek approval from the IRB board that originally approved the 
trial before including the data in the analysis.
Comparison of baseline measures between trials
Before conducting analyses to estimate the effects of antifibri-
nolytic treatment, we will present descriptive analyses to show 
any differences in baseline characteristics between the types of 
patient enrolled in the included trials. We will present statistical 
comparisons of baseline means (t-tests) and prevalence measures 
(chi-squared tests) for patients enrolled in the included trials.
Intention to treat analyses and missing data
We aim to include all randomised patients, regardless of whether 
they received the trial treatment, on an intention-to-treat basis. 
For patients who withdraw consent after randomisation, data 
collected up to the point of withdrawal will be included. We do 
not anticipate substantial amounts of missing data for the primary 
outcome and subgroup factors. However, in the event that missing 
data is significant we will use a range of statistical approaches and 
will assess the impact of missing data on the results by conduct-
ing sensitivity analyses. We do anticipate substantial missing data 
for neuro-radiological outcomes measures, since many patients 
will not be scanned before and/or after randomisation because 
they died or did not require re-scanning. Indeed, the pilot data 
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from the CRASH-3 Intracranial Bleeding Mechanistic Sub-study 
suggests that post-randomisation scans are less likely to be done 
in patients who die soon after admission (i.e. patients with a low 
Glasgow Coma Scale score) but also in patients who have a mild 
head injury (i.e. patients with a high Glasgow Coma Scale score) 
who do not need a second scan. We will report the number of 
patients without pre- and post-randomisation scans by treatment 
arm. If the outcome of interest (haemorrhage expansion) is asso-
ciated with the reason the data are missing (for example, patients 
with haemorrhage expansion may be more likely to die before 
the second scan), imbalance in missing data by treatment group 
could cause bias. If we suspect data are missing not at random, we 
will assess the impact of this in sensitivity analysis.
Primary outcomes
There are two co-primary outcomes.
1) Death in hospital at end of trial follow-up among patients 
treated within three hours of injury or stroke onset.
2) Death in hospital or dependency at end of trial follow-up among 
patients treated within three hours of injury, or stroke onset. 
Dependency will be defined as a score of 4–6 on the modified 
Rankin scale among TICH-2 patients and a score of ≥12 on the 
Disability Rating Scale in CRASH-3 patients.
Although some trials recruit patients up to eight hours after 
injury or stroke onset, evidence from pathophysiological studies 
and trials of TXA in extra-cranial bleeding strongly suggest that 
treatment beyond three hours of onset is unlikely to improve 
outcomes. We believe that this is even more likely in the context 
of intracranial bleeding because the majority of bleeding occurs 
within the first few hours of injury17. We will examine the effects 
of antifibrinolytics on death using logistic regression. We will 
report treatment effects using odds ratios (OR) and 95% confi-
dence intervals (95% CI). We will first assess the homogeneity of 
the treatment effects between trials by estimating a random effects 
model where both the intercept and the treatment effect will be 
allowed to have a distribution across trials. The variance of the 
distribution of the treatment effect will give us an idea of the 
heterogeneity between trials. However, if only very few trials are 
included in the meta-analysis, instead of a random effects model 
we will examine the heterogeneity by including an interaction 
term between the treatment and the trial variable and reporting 
the p-value.
We will also plot a Kaplan-Meier curve for survival analysis 
comparing outcome of patients in treatment and placebo arms.
Subgroup analyses for co-primary outcomes
(a) Time to treatment – Does treatment delay modify the pro-
portional effect of antifibrinolytics on death and or dependency 
taking into account any other independent relationships between 
severity/age and the treatment effect?
We define treatment delay as the time from injury or symptom 
onset to randomisation. We appreciate that there will be some 
time interval between randomisation and treatment delivery 
but not all trials record the time of treatment delivery and we 
expect this interval to be short (0–15 minutes). We expect that 
the effect of TXA will vary by time to treatment with early 
treatment being most effective. Initially, we will plot treatment 
effects and 95% confidence intervals by 60-minute intervals of 
treatment delay. In addition, we will assess the impact of treat-
ment delay on treatment effect in a regression analysis that 
includes terms for hours of treatment delay and its square 
(because of potential non-linearity of the treatment effect), and 
interactions between these two variables with treatment group. 
To explore the interaction between treatment effect and time, 
we will use the data on all treated patients and not only those 
treated within three hours.
We will check for potential heterogeneity of these effects 
across trials, by running a random effects models allowing the 
coefficients to vary randomly across trials. However, if we only 
include a small number of trials, instead of the random effects 
model we will include a triple interaction between the terms for 
treatment delay, the treatment group, and the trial.
Because severity of intracranial bleeding and age could con-
found impact of treatment delay on treatment effectiveness, we 
will control all models for GCS and age (10-year intervals) 
which are strong risk factors for death. If the above regression 
analyses indicate a trend towards decreasing treatment effective-
ness with increasing delay, we will estimate the time at which 
the estimated odds ratio reaches the null (1.00) and the time at 
which the lower 95% confidence interval reaches the null.
Because there is strong prior evidence to expect a time to 
treatment interaction, two-way interaction tests will be regarded 
as statistically significant and thus providing evidence of effect 
modification if the two-sided P-value is less than 0.05.
Assessment of regression dilution bias: Because time of 
bleeding onset (i.e. time of injury or stroke onset) is often 
uncertain, measurement error is inevitable. We will investigate 
the impact of misclassification of treatment delay in sensitivity 
analyses using a range of plausible errors. We will add a random 
number of minutes to the treatment delay using a uniform distri-
bution with a constant minimum set at 0 and four sets of maxi-
mum value: 15, 30, 45 and 60 minutes. The corrections are based 
on data from an audit of treatment delay in a large clinical trial 
in traumatic brain injury (the CRASH-3 trial) in which treatment 
delay was rarely over-estimated but often under-estimated 
(mean under-estimation 51 minutes). For each of the four maxi-
mum values, we will re-estimate the final model 100 times to 
obtain ranges for the time to treatment interaction.
(b) Severity of intracranial bleeding – Does severity modify the 
proportional effect of antifibrinolytics taking into account any 
other independent relationships treatment delay or age and 
treatment effect?
We will examine the effect of antifibrinolytics on death strati-
fied by baseline severity. We will examine three subgroups based 
on baseline GCS: mild (GCS 13-15), moderate (GCS 9-12) and 
severe (GCS 3-8). We will use interaction tests to see whether 
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the effect of the treatment (if any) differs across these subgroups. 
We will also assess the impact of baseline severity on the treat-
ment effect in a regression analysis that includes continuous terms 
for severity and its square (because of potential non-linearity 
of the treatment effect). Because treatment delay and age could 
confound impact of severity on treatment effectiveness, we will 
control all models for treatment delay and age (10-year 
intervals) and their interaction with treatment. Unless there is strong 
evidence against the null hypothesis of homogeneity of effects 
(i.e. p<0.01) the overall odds ratio will be considered the most 
reliable guide to the approximate treatment effect in all patients.
(c) Age – Does the patient’s age modify the proportional effect 
of antifibrinolytics taking into account any other independent 
relationships with treatment delay or severity and the treatment 
effect?
We do not expect the proportional benefits of antifibrinolytics to 
reduce with increasing patient age. However, because traumatic 
and spontaneous intracranial bleeding are increasingly common 
in older patients, who are sometimes denied potentially effec-
tive treatments on the basis that there is insufficient evidence in 
older patients, it will be important to consider this question. We 
will therefore conduct regression analyses to assess the impact of 
age on the treatment effect in a regression analysis that includes 
continuous terms for age and its square (because of potential 
non-linearity of the treatment effect) and their interaction with 
treatment. Because treatment delay and severity could confound 
the effect of age on treatment effectiveness, we will control all 
models for treatment delay and severity and their interactions 
with treatment. Unless there is strong evidence against the null 
hypothesis of homogeneity (i.e. p<0.01), the overall odds ratio 
will be considered the most reliable guide to the approximate 
treatment effect in all patients.
Secondary outcomes
We will assess the effect of TXA on the following secondary 
outcomes in all patients, irrespective of time of treatment.
Clinical outcomes
•    Death or dependency
•    Dependency score
•    Cause specific mortality
•    Stroke and other vascular occlusive events
•    Seizures
Neuro-radiological outcomes
•    The total volume of intracranial bleeding after randomisa-
tion (adjusting for total volume of intracranial bleeding at 
baseline if baseline volume is available)
•    New focal ischaemic lesions (ischaemic lesions which 
appear on a post-randomisation scan but not on the 
pre-randomisation scan if the pre-randomisation scan is 
available)
•    Frequency of progressive haemorrhage (number of patients 
with a post-randomisation CT scan with total haemor-
rhage volume of more than 33% of the volume on the pre- 
randomisation scan)
•    The total volume of intracranial bleeding after neurosur-
gery (adjusting for total volume of intracranial bleeding at 
baseline if baseline volume is available)
A selection of approximately 1000 patients in the CRASH-3 trial 
are included in a neuro-radiological sub-study in which a simple 
validated rating scale (ABC/2) is used to measure intracranial 
haemorrhage. The majority of patients in the TICH-2 trial undergo 
brain imaging before and after randomisation. The TICH-2 trial 
also uses the ABC/2 method to estimate intracranial haemorrhage.
We will conduct subgroup analyses to examine whether the effect 
of TXA on neuro-radiological outcomes varies by haematoma 
type (intra-parenchymal, intra-ventricular, epidural, subdural, sub-
arachnoid, lobar, deep). Intra-parenchymal haemorrhage is at the 
greatest risk of expansion and TXA may be most likely to reduce 
bleeding of this type. Intra-ventricular haemorrhage and clots 
could block the flow of cerebrospinal fluid and thereby increase 
the risk of hydrocephalus. TXA therefore may be ineffective or 
even harmful for patients with this type of bleeding. We will use 
interaction tests to see whether the effect of TXA (if any) differs 
across these subgroups. Unless there is strong evidence against 
the null hypothesis of homogeneity of effects (i.e. p<0.001) the 
overall relative risk will be considered the most reliable guide 
to the approximate relative risks in all subgroups.
Conclusions
The results of this IPD meta-analysis will provide a better 
understanding of the balance of risk and benefits of antifibri-
nolytic treatment in patients with intracranial haemorrhage and 
how they vary by time to treatment. This knowledge will enable 
better targeting of the use of antifibrinolytics and will influence 
treatment protocols.
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JAMA by Gamble et al , with a very useful accompanying Editorial by Demets .  It would be reasonable
for the authors to consider whether they have covered the key points set out in the new guidance
document (but interpreted in the light of the comments in the accompanying Editorial); i.e. there is no
need slavishly to adhere to the guidance, but rather simply to ensure there are no major omissions in this
SAP.
Specific comments
Searches.  The Cochrane Stroke Group’s register of stroke trials would be worth searching
separately to Central either via the public portal   or by contact with the Strokewww.askdoris.org
Group Editorial Base team, since the register contains more information than is downloaded to
Central. 
 
Inclusion of studies with > 1000 patients.  This seems sensible.  The authors might in addition
consider at least noting the smaller studies identified by the searches and reporting the name, and
size of randomised trials with < 1000 patients to give an idea of the totality of evidence (and sadly,
an idea of the research waste involved in such small uninformative studies), but not include them in
analyses for fear of small study bias etc, etc.
 
Duration of scheduled follow up in CRASH3 and TICH-2 is different; 28 days in CRASH-3 and 90
days in TICH-2.  Some consideration should be given for analyses of death and outcomes around
30 days in both trials to give greater clarity to readers on effects on early outcomes, as well as
effects on outcomes at final follow-up.
 
Adjustment for baseline severity.  GCS is measured in CRASH-3, and in TICH-2, the protocol
states NIHSS is one of the minimisation variables    but there is no specific mention of GCS (if
GCS is not routinely collected pre-randomisation, the protocol should specify how the NIHSS will
be mapped onto GCS or vice versa.).  If TICH-2 does measure GCS pre-randomisation, then it
should just be made clear in the SAP.
Analyses of neuroradiological outcomes.  These seem reasonable.   
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